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Transbuccal drug delivery is an attractive way of administration since several well-known advantages
are provided, especially with respect to peroral management. Carbamazepine (CBZ) is an anticonvulsant
which is useful in controlling neuropathic pain, and it is currently administered by peroral route,
although its absorption and bioavailability is limited due to various factors. The oral cavity could be
an interesting site for transbuccal CBZ delivery due to two properties: slow administration of constant
low drug doses and less dose-related side effects. However, in transbuccal absorption a major limitation
could be the low permeability of the mucosa which results in low drug bioavailability; thus the aptitude
of the drug to penetrate the buccal mucosa has to be assessed by using tissue models resembling human
normal mucosa. In our experience, CBZ well permeates mucosal membranes. In order to assess the
efficacy of CBZ transbuccal delivery and to verify the reliability of these tissues in permeability testing
before and after the passage of CBZ, the histo-morphological features of reconstituted human oral
(RHO) epithelium (E) and buccal porcine mucosae were investigated. Significant histological changes
due to CBZ passage were observed both in RHO-E and porcine mucosa. The main findings detected in
RHO samples were cellular swellings with a signet ring-like appearance, nuclear swelling, prominent
nucleoli lined against the nuclear membrane and the presence of keratohyalin granules. The most
striking finding regarding porcine buccal mucosa was a cytoplasmic vacuolization, mainly involving the
basal layer.
Buccal delivery offers a feasible alternative to
parenteral delivery and many advantages to per os
administration, e.g. reduced first pass metabolism,
reduced drug decomposition and adverse effects,
improved drug bioavailability, and often a more
rapid onset of therapeutic effect (1).
Carbamazepine (CBZ) is a drug which could be
very attractive if delivered transbuccally. CBZ is
really useful in controlling neuropathic pain (2) and
it is currently delivered per os, using doses ranging
from 200-600 mg/die administered in divided doses.
Following peroral administration, absorption and
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bioavailability of CBZ is limited due to its physico-
chemical and pharmacokinetic parameters. The oral
cavity could be an attractive site of delivery also for
CBZ due to slow and constant administration of low
drug doses with less dose-related side effects.
A comprehensive knowledge of the structure of
human buccal mucosa, permeability barriers and
transport pathway mechanisms is important for
drug development and optimization, and for related
transbuccal delivery systems. Studies on drug
transport across buccal epithelium have been carried
out in the past using several methodologies. Indeed,
the reduced availability of human buccal tissue
for experimental use has led to the development
of cultured tissues and/or application of animal
tissue which resembles human buccal mucosa.
Two laboratory models have been largely used in
recent decades for rapid and efficient examination
of permeability, metabolism and toxicity of drugs: in
vitro tissue-engineered oral mucosal equivalents (3-
4), and ex vivo buccal mucosa from various animal
models (5).
The Reconstituted Human Oral (RHO) epithelium
(E) is a cell culture model obtained from TRl46 cell
line. This type ofcells, coming from human neck node
metastases ofa buccal carcinoma, when cultivated in
vitro on polycarbonate filters in defined conditions,
form an epithelial tissue resembling the mucosa of
the oral cavity (6-7). Due to its similarities to human
epithelium, RHO-E has recently been utilized as a
valuable model for studying drug transport (8).
Many animal models of oral mucosa have
been used for ex vivo permeability studies: the
most commonly used are dogs, rabbits, hamsters,
Rhesus monkeys, guinea pigs, rats and pigs (5).
When choosing a particular animal model, the
main requirement is the resemblance of animal oral
mucosae to human oral mucosae regarding ultra-
structure and enzyme activities, including physical
and metabolic barriers, although no animal tissues
can completely resemble human tissue. The porcine
buccal mucosa has been used most frequently by
various leading research groups as a representative
model, resembling human buccal epithelium more
closely than any other animal model in terms of lipid
content and composition, membrane morphology
and permeability barrier functions, structure and
composition (5). In particular, the pig seems to be
the most attractive animal model for buccal drug
delivery since its buccal and mouth floor mucosae
contain unkeratinised tissue, as in human beings.
Other advantages are their inexpensive handling
and maintenance costs (9). Pig excised buccal tissue,
mounted in an appropriate diffusion cell system
(mainly the vertical Franz-type diffusion cells), has
been used in most ex vivo studies (10).
The main objectives of this study are to assess
the histo-morphological features of RHO epithelium
and buccal porcine tissues before and after CBZ
passage and to verify the reliability of these tissues
in the permeability testing of CBZ and its potential
transmucosal delivery.
MATERIALS AND METHODS
Permeation test using RHO
The permeation of CBZ was investigated in vitro
by measuring drug fluxes through RHO-E, cultured on
permeable polycarbonate inserts (11). Briefly, mucosal
specimens, non-keratinised type (RHO/S/l2), were
purchased from Skinethic Laboratories" (Nice, France).
Upon arrival, the bags containing the inserts with cultured
cell layers were opened under sterile airflow. Each insert
(0.5 em') containing the epithelial tissue was removed, and
any remaining agarose adhering to its walls was rapidly
removed by gently blotting it on sterile filter paper, and it
was then placed in culture dishes filled with maintenance
medium (SkinethicvLab. Nice, France). Some inserts, not
subjected to the experimental phase, were used as blank.
Those samples subjected to the experimental phase in
absence of drug were used as permeation controls. The
remaining inserts were used for drug permeability tests.
Experiments were performed at a constant temperature of
37°C, using the Transwel1 diffusion cell system (Fig. la)
as a two-compartment open model (11).
The epithelial tissue was cut out from the plastic insert,
together with the polycarbonate filter, using a sharp scalpel
for histological analysis. The filter samples were fixed in
10% neutral-buffered formalin for two hours, washed in
water for I hour, dehydrated in graded ethanol (60%,
80%, 90%, 95%, and 100%) and, after permeation in
xylene, embedded in paraffin using standard procedures.
Formalin-fixed, paraffin-embedded samples were cut into
4-Jlm-thick sections on a microtome with a disposable
blade and conventionally stained with hematoxylin-and-
eosin.
Permeation test using porcine mucosa
The drug permeation through the porcine buccal
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Flux and permeabil ity coefficient values, obtained
as average value of six replicated experiments, were
reported with the standard deviations. All differences
were statistically evaluated by the Student's t-test with the
minimum levels of significance with P ::::0.05.
Histological criteria
Slides stained with hematoxylin-and-eosin were
evaluated using optical microscopy in a blind and
independent fashion. Digital photomicrographs ofrelevant
fields were taken at 250x, 400x and IOOOx magnification.
Two different types of negative controls were included
in the histomorphological analysis: blank controls and
permeation controls. As the aim ofthe histomorphological
analysis was to evaluate the pathological changes
occurring in cell morphology and tissue organization,
samples treated with 5-fluorouracil (5-Fu) were included
in the analysis as markers of cytopathic alterations. The
presence of acanthosis, hyper/parakeratosis, koilocytosis,
corneal pearls, papillomatosis and phlogosis were
evaluated for histological analysis.
Fig. 1. a) Schematic representation of the Transwell
system, an open two-compartment model used for the
in vitro permeation tests with RHO-E: b) Schematic
representation of the Franz-type diffusion cell system: it
is an open bi-compartmental model in which the donor
compartment was .filled with a solution containing CBZ
and the acceptor compartment was filled with a solution
simulating plasma.
mucosa was evaluated using Franz type diffusion cells
(Fig. Ib) (II). Mucosal specimens were obtained from
tissue, which had been removed from freshly slaughtered
domestic pigs. After sampling, all specimens were
immediately placed in a refrigerated transport box and
transferred to the laboratory within I h. Excesses of
connective and adipose tissue were trimmed away until
slides 0.8 ± 0.1 mm thick were obtained. The specimens
were stored at -40°C for periods of up to six months.
Some specimens, not subjected to the experimental
phase, were used as blank . Those specimens subjected to
the experimental phase in absence of drug were used as
permeation controls. The remaining specimens were used
for drug permeability tests. Experiments were performed
at a constant temperature of 37°C. Mucosal specimens
were fixed in formalin, embedded in paraffin, cut into 4-
um-thick sections and stained with haematoxylin-eosin,
using the above-mentioned standard procedures.
RESULTS
The CHZ permeation pattern through buccal
mucosae was investigated by using two different bi-
compartmental open systems: a Transwell diffusion
cells system for RHO-E (in vitro experiments) and
Franz cells for porcine buccal mucosae (ex vivo
experiments) . The permeability tests were carried out
for 3 hours in order to avoid changes in permeability
characteristics of the tissues.
In both cases, the amount of CHZ permeated per
unit surface area was plotted versus time (Figs . 2 and
3). Permeation through RHO-E was characterized
by an initial lag time of about 5 min (Fig. 2b),
during which CHZ diffused into the blood stream,
although the amount of transferred drug was not
easily detectable . The steady state flux was reached
in 12 min. For porcine mucosal tissue the steady
state flux was reached in about 30 min, as shown in
the linear part of the plot in Fig. 3. The linear part
of the curves was used for the determination of the
steady state flux values (Js) through the membrane
and the permeability coefficients (Kp), by means of
a standard resolution of the Fick equation for steady
state membrane transport. Js and Kp values for CHZ
in vitro experiments were 7,10,2 mg/cm/h and 0.23
cm/h, respectively, whereas Js and Kp for the ex vivo






























Fig. 2. In vitro permeation oJCBZ throughout reconstituted human oral epithelium: a) cumulative amount-time profile;
b) results observed in thefirst 30 minutes ojpermeation show an initial lag time ojabout 5 min. Drugflux was calculated
at the steady state from the slope ofthe linear portion ofthe plot.
experiments were 1.81.10-2 mg/cm/h and 4.57,10-2
cm/h, respectively. As expected, the flux through the
mucosae was extensively affected by the thickness
of the membrane.
After permeability tests, significant histological
changes due to permeability of CBZ were observed
in the RHO and porcine mucosae. Regarding the
former, the two types of negative controls, blank
controls and permeation controls revealed an
unkeratinized squamous cell epithelium, composed
of an average of 5-8 cellular layers. No significant
cytological or architectural changes were highlighted
(Fig.4a).
The histological analysis of RHO samples
submitted to CBZ diffusion revealed pronounced
alterations involving the entire thickness of the
membrane; cellular swelling with a signet ring-like
appearance, nuclear swellings, prominent nucleoli
lined against the nuclear membrane and the presence
of keratohyalin granules were the main findings
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Fig. 3. Cumulative amount-time profile ofCBZ permeated across porcine buccal mucosa during ex vivo experiments.
(Fig. 4b). Apoptotic figures and signs of abrupt
keratinisation were occasionally observed together
with cellular disarray with loss of cell polarity (Fig.
4c). In particular, the cells appeared vacuolated
and this is likely ascribable to the presence of an
intracytoplasmic fatty content due to the presence of
CBZ. Other samples revealed less marked alterations
with an effacement of the upper 2/3 and a preserved
basal layer.
The negative controls of porcine buccal mucosae
showed unkeratinized squamous cell epithelia,
composed of an average of 20-30 cellular layers. No
significant cytological or architectural changes were
observed. A slight degree of dysplasia was observed
in some samples, as maturational defects of the
intermediate layer, and a mild loss of nuclei polarity
(Fig.4d).
.The histological evaluation of porcine buccal
specimens, submitted to CBZ diffusion, revealed
alterations similar to those of the RHO samples.
No sign of phlogosis was found in any of the
mucosal specimens. The most striking finding was
a cytoplasmic vacuolization which mainly involved
the basal layer (Fig. 5a). A moderate degree of
acanthosis with some piknotic nuclei was present,
but neither papillomatosis, nor hyper/parakerathosis,
nor hom pearls were detected (Fig. 5b).
The RHO and porcine samples treated with 5-
Fu, as marker of cytopathic alterations, showed
cytopathic effects more evident than those found in
all samples treated with CBZ (Fig. 5c, d).
DISCUSSION
Anticonvulsants are a group of medicines
commonly used for treating 'fits' or epilepsy, but
which are also effective for treating neuropathic
pain. Of these, CBZ is currently the only medication
carrying an FDA-approved indication for neuropathic
pain which is specified for trigeminal neuralgia and
glossopharyngeal neuralgia (12-14). CBZ acts pre-
synaptically and post-synaptically by slowing the
recovery of sodium ion channels after activation
(15). Therapeutic plasma levels range from 4 to 12
ug/ml, and the half-life of CBZ varies from 10 to
25 hrs in adults, depending on the patient's age. The
most common side effects of CBZ are dizziness,
giddiness and dyspepsia. These symptoms are dose-
related, and can be minimized by starting with low
doses (16).
CBZ is currently administrated at a dosage of
200-600 mg daily, given in divided doses (e.g. every
4 or 8 hours), starting with low initial doses.
Following application to mucosae, the
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Fig. 4. a) RHO sample not subjected to the experimental phase. The picture shows a non-keratinized squamous cell
epithelium (five cellular layers) with no significant cytological or architectural changes (H-E x400); b) RHO sample
characterized by marked cellular disarray with loss ofcell polarity, signs ofmicrovacuolization and sporadic piknotic
nuclei (see arrows) (H-E x400); c) RHO sample submitted to CBZ diffusion shows pronounced alterations involving the
whole membrane thickness. cytoplasmic and nuclear swelling. Prominent nucleoli lined along nuclear membrane and
keratohyalin granules are visible (H-E x250); d) Porcine blank control. The picture shows a non-keratinized squamous
cell epithelium composed by an average of20-30 cellular layers with slight degree ofdysplasia in theform 0.(maturational
defects (see arrows) (H-E x250).
c d
Fig. 5. a) This section shows a moderate degree ofcytoplasmic vacuolization mainly involving the basal layer
along with slight acanthosis (H-E x400); b) At higher magnification nuclear picnosis is clearly evident (H-E
x1000); c) Porcine buccal specimen treated with cytotoxic 5-Fu 1% with acanthosis and manypyknotic nuclei;
d) RHO sample treated with cytotoxic 5-Fu 1% showing marked nuclear changes with prominent nucleoli and
apoptotic cells (H-E x400).
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therapeutic efficacy of a drug for transepithelial
delivery mainly depends on its ability to penetrate
the tissue fast enough to provide the required
plasma concentrations, which result in the desired
pharmacological activity. Indeed, the most important
limitation in the development of a buccal drug
delivery device could be the low permeability of
the buccal mucosae. To assess the ability of CBZ
to penetrate the barrier and define the permeation
pattern, permeation tests were performed using two
different bi-compartmental open systems. Firstly,
we used the RHO-E model. This tissue, at the 12th
day of culture, has about 4-6 cell layers and it is
about 120 f.1m thick (6) whereas the human buccal
mucosa comprises approximately 40-50 cells and it
is 500-800 f.1m thick (about 12.5-20.0 f.1m for each
layer). Secondly, to obtain further permeation data,
ex vivo permeation tests, using 800 urn thick porcine
buccal specimens resembling human mucosa, were
performed. In both cases the results of permeability
tests were expressed using drug flux values (Js)
through the membrane and permeability coefficients
(K ). CBZ, when topically administered, effectively
p
permeated the membrane and no drug was entrapped
in the cell layers, thus suggesting that the membrane
did not constitute a limitation to absorption.
The aim ofthis study was to perform a histological
analysis of epithelial specimens. The main finding
was the diffuse clear cytoplasmic appearance, which
is probably an effect of intracellular fat, and likely
due to intracellular drug diffusion. This finding was
abundantly present in RHO samples and specimens
of porcine mucosae; the discrepancy regarding
the degree of involvement (transmural in RHO
membranes, mainly concentrated in the basal layer
in the ex vivo specimens) has been ascribed to the
different thicknesses of the samples. The cytopathic
effects observed in RHO and porcine samples treated
with CBZ were less intense than those found in
samples treated with the potent cytotoxic drug 5-Fu,
thereby suggesting that CBZ is not a cytotoxic drug.
On the basis of our results, we have established
that CBZ permeates mucosal membranes well,
although its permeation across epithelium did cause
some cyto-architectural changes. CBZ is not a
cytotoxic drug but further investigation is required
in.order to assess its potential for transmucosal drug
delivery.
RHO-E (in vitro) and porcine buccal mucosa
(ex vivo) have been shown to be two reliable and
reproducible permeation test models. Even if we
observed some minor different histomorphological
behaviour, ascribable to the diverse thickness of the
tissues used, both models have similar performances
after drug passage. The validity of these mucosal
models is confirmed by several data, indicating a
good correlation of human normal mucosa with
porcine and tissue-engineered human oral mucosal
equivalents in terms of histology, ultrastructure and
organization of the permeability barrier.
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